Maintenance Olaparib New Standard in Pancreatic Cancer?
- PMID: 31164341
- DOI: 10.1158/2159-8290.CD-NB2019-065
Maintenance Olaparib New Standard in Pancreatic Cancer?
Abstract
In a phase III trial, olaparib maintenance therapy significantly extended progression-free survival and duration of response in patients with BRCA-mutated metastatic pancreatic cancer who responded to platinum-based chemotherapy, compared with a placebo. Based on the findings, which were presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, IL, maintenance olaparib is likely to become a new treatment option for these patients.
©2019 American Association for Cancer Research.
Comment on
-
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157963 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical